In vitro and in vivo anti-inflammatory activity of the new glucocorticoid ciclesonide

被引:93
作者
Stoeck, M
Riedel, R
Hochhaus, G
Häfner, D
Masso, JM
Schmidt, B
Hatzelmann, A
Marx, D
Bundschuh, DS
机构
[1] ALTANA Pharma AG, D-78467 Constance, Germany
[2] Univ Florida, Coll Pharm, Gainesville, FL USA
[3] Elmuquim Pharmaceut, Madrid, Spain
关键词
D O I
10.1124/jpet.103.059592
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The glucocorticoid ciclesonide is the 2'R-epimer of 2'-cyclohexyl-11 beta-hydroxy-21-isobutyryloxy-16bH- dioxolo[5', 4': 16,17] pregna-1,4- diene-3,20-dione. The active metabolite desisobutyrylciclesonide (des-CIC) is derived from ciclesonide by esterase cleavage of isobutyrate at the C21 position. The relative binding affinities at the rat glucocorticoid receptor were dexamethasone, 100; ciclesonide, 12; des-CIC, 1212; and budesonide, 905. Des-CIC potently inhibited the activation of murine and human lymphocytes in a series of different in vitro systems. With the exception of concanavalin A-stimulated rat spleen cells, des-CIC was more potent than the parent compound. Des-CIC compared well with budesonide in all in vitro systems. Furthermore, the respective 2'S-epimers were always significantly less potent than the 2'R-epimers. In vivo, ciclesonide ( intratracheal administration), des-CIC, and budesonide inhibited antigen-induced accumulation of eosinophils, protein, and tumor necrosis factor-alpha into the bronchoalveolar lavage fluid of ovalbumin-sensitized and - challenged Brown Norway rats with an ED50 value ranging from 0.4 to 1.3 mg/kg, indicating similar potency, which suggests in vivo activation of the parent compound. Ciclesonide and budesonide inhibited the bradykinin-induced protein leakage into the rat trachea. In the rat cotton pellet model, ciclesonide inhibited granuloma formation (ED50: = of 2 mug/pellet), whereas budesonide and des-CIC were 15- and 20-fold less active; thymus involution was induced with an ED50 of 303, 279, and 154 mug/pellet, respectively. When applied orally to rats for 28 days, ciclesonide showed low potency in reducing weight of thymus and adrenals, suggesting low oral bioavailability. The in vivo data on ciclesonide highlight its effective local action and a reduced potential for side effects.
引用
收藏
页码:249 / 258
页数:10
相关论文
共 35 条
[1]   Glucocorticoid-regulated transcription factors [J].
Adcock, IM .
PULMONARY PHARMACOLOGY & THERAPEUTICS, 2001, 14 (03) :211-219
[2]   Effect of intranasal corticosteroids on release of cytokines and inflammatory mediators [J].
Bachert, C ;
Geveart, P .
ALLERGY, 1999, 54 :116-123
[3]   DRUG-THERAPY - INHALED GLUCOCORTICOIDS FOR ASTHMA [J].
BARNES, PJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (13) :868-875
[4]   Ciclesonide, a novel "on site activated" inhaled corticosteroid with potent anti-inflammatory actions in the airways [J].
Belvisi, M ;
Bundschuh, D ;
Stoeck, M ;
Wicks, S ;
Underwood, S ;
Battram, C ;
Webber, S ;
Haddad, EB ;
Foster, M .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2002, 109 (01) :S37-S37
[5]   New glucocorticosteroids with an improved therapeutic ratio? [J].
Belvisi, MG ;
Brown, TJ ;
Wicks, S ;
Foster, ML .
PULMONARY PHARMACOLOGY & THERAPEUTICS, 2001, 14 (03) :221-227
[6]  
BENRHOUMA K, 1994, ARCH INT PHYSIOL BIO, V102, P97
[7]   Prednisolone treatment in asthma - Reduction in the numbers of eosinophils, T cells, tryptase-only positive mast cells, and modulation of IL-4, IL-5, and interferon-gamma cytokine gene expression within the bronchial mucosa [J].
Bentley, AM ;
Hamid, Q ;
Robinson, DS ;
Schotman, E ;
Meng, Q ;
Assoufi, B ;
Kay, AB ;
Durham, SR .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1996, 153 (02) :551-556
[8]  
BODOR N, 1988, TOPICAL CORTICOSTERO, P13
[9]   CORTICOSTEROID INHIBITION OF AIRWAY MICROVASCULAR LEAKAGE [J].
BOSCHETTO, P ;
ROGERS, DF ;
FABBRI, LM ;
BARNES, PJ .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1991, 143 (03) :605-609
[10]   ATTENUATION OF BRADYKININ-INDUCED MUCOSAL INFLAMMATION BY TOPICAL BUDESONIDE IN RAT TRACHEA [J].
BRATTSAND, R ;
ODONNELL, SR ;
MILLERLARSSON, A ;
RAUCHLE, KL .
AGENTS AND ACTIONS, 1991, 34 (1-2) :200-202